<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4520">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03048084</url>
  </required_header>
  <id_info>
    <org_study_id>77353</org_study_id>
    <nct_id>NCT03048084</nct_id>
  </id_info>
  <brief_title>Seizure Treatment in Glioma</brief_title>
  <acronym>STING</acronym>
  <official_title>A Randomized Controlled Trial Comparing a Treatment Strategy With Levetiracetam and Valproic Acid in Glioma Patients With a First Seizure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Center Haaglanden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, treatment with a specific anti-epileptic drug mainly depends on the physicians'
      preference, as there are no studiessupporting the use of one specific anticonvulsant in
      glioma patients. The overall aim of this randomized controlled trial is to directly compare
      the effectiveness of treatment with levetiracetam or valproic acid in glioma patients with a
      first seizure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, treatment of glioma patients with a specific anti-epileptic drug (AED) mainly
      depends on the physicians' preference, as there is no robust evidence from randomized
      controlled trials supporting the use of one specific anticonvulsant above the other in
      glioma patients.

      Levetiracetam and valproic acid are the most commonly used AEDs in glioma patients. Both
      drugs are used for the treatment of seizures, have similar toxicity profiles and are
      non-enzyme inducing AEDs, therefore not interfering with chemotherapeutic drugs. However, it
      is not known whether one drug is more effective than the other in reducing seizures.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2017</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing seizure freedom at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>The percentage of patients with ongoing seizure freedom at 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to 6 months seizure freedom</measure>
    <time_frame>0, 1, 3, 6, 9, 12, 15, 18, 21, 24, 30 and 36 months or 0, 1, 6, 12, 18, 24 and 30 months, depending on a 3-monthly or 6-monthly follow-up schedule respectively</time_frame>
    <description>Time to 6 months seizure freedom</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizure outcome at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Seizure outcome at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>0, 1, 3, 6, 9, 12, 15, 18, 21, 24, 30 and 36 months or 0, 1, 6, 12, 18, 24 and 30 months, depending on a 3-monthly or 6-monthly follow-up schedule respectively</time_frame>
    <description>Adverse effects of the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisation rate</measure>
    <time_frame>0, 1, 3, 6, 9, 12, 15, 18, 21, 24, 30 and 36 months or 0, 1, 6, 12, 18, 24 and 30 months, depending on a 3-monthly or 6-monthly follow-up schedule respectively</time_frame>
    <description>hospitalization rate due to treatment failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>0, 3, 6, 9, 12, 15, 18, 21, 24, 30 and 36 months or 0, 6, 12, 18, 24 and 30 months, depending on a 3-monthly or 6-monthly follow-up schedule respectively</time_frame>
    <description>Health-related quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive complaints</measure>
    <time_frame>0, 3, 6, 9, 12, 15, 18, 21, 24, 30 and 36 months or 0, 6, 12, 18, 24 and 30 months, depending on a 3-monthly or 6-monthly follow-up schedule respectively</time_frame>
    <description>Cognitive complaints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood</measure>
    <time_frame>0, 3, 6, 9, 12, 15, 18, 21, 24, 30 and 36 months or 0, 6, 12, 18, 24 and 30 months, depending on a 3-monthly or 6-monthly follow-up schedule respectively</time_frame>
    <description>Anxiety and depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance Status</measure>
    <time_frame>0, 3, 6, 9, 12, 15, 18, 21, 24, 30 and 36 months or 0, 6, 12, 18, 24 and 30 months, depending on a 3-monthly or 6-monthly follow-up schedule respectively</time_frame>
    <description>Karnofsky Performance Status Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epilepsy burden</measure>
    <time_frame>0, 3, 6, 9, 12, 15, 18, 21, 24, 30 and 36 months or 0, 6, 12, 18, 24 and 30 months, depending on a 3-monthly or 6-monthly follow-up schedule respectively</time_frame>
    <description>Epilepsy burden</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment response</measure>
    <time_frame>0, 1, 3, 6, 9, 12, 15, 18, 21, 24, 30 and 36 months or 0, 1, 6, 12, 18, 24 and 30 months, depending on a 3-monthly or 6-monthly follow-up schedule respectively</time_frame>
    <description>Treatment response (e.g., maximum dosage of AED, use of add-on AED)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>0, 1, 3, 6, 9, 12, 15, 18, 21, 24, 30 and 36 months or 0, 1, 6, 12, 18, 24 and 30 months, depending on a 3-monthly or 6-monthly follow-up schedule respectively</time_frame>
    <description>Progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>0, 1, 3, 6, 9, 12, 15, 18, 21, 24, 30 and 36 months or 0, 1, 6, 12, 18, 24 and 30 months, depending on a 3-monthly or 6-monthly follow-up schedule respectively</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>Levetiracetam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this treatment arm will receive levetiracetam monotherapy. The dosage depends on the specific treatment step, as indicated in the protocol. In step 1, patients will receive 2x500 mg/d levetiracetam in the form of tablets. In step 2, dosage is increased to 1x250 plus 1x500 mg/d and in step 3 to 2x1000 mg/d levetiracetam. In step 4, levetiracetam is increased to 2x1500mg/d. In the fifth treatment step, patients will receive 2x1500 mg/d levetiracetam, and another AED will be added. The type and dosage of this add-on AED is according to the physician's preference, but in line with current clinical practice in the Netherlands.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valproic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this treatment arm will receive valproic acid monotherapy. The dosage depends on the specific treatment step, as indicated in the protocol. In step 1, patients will receive 2x500 mg/d valproic acid in the form of tablets. In step 2, dosage is increased to 1x250 plus 1x500 mg/d and in step 3 to 2x1000 mg/d valproic acid. In step 4, valproic acid dosage is increased to a maximum of 2x1250mg/d. In the fifth treatment step, patients will receive 2x1250mg valproic acid, and another AED will be added. The type and dosage of this add-on AED is according to the physician's preference, but in line with current clinical practice in the Netherlands.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam</intervention_name>
    <description>Antiepileptic drug levetiracetam</description>
    <arm_group_label>Levetiracetam</arm_group_label>
    <other_name>Keppra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproic Acid</intervention_name>
    <description>Antiepileptic drug valproic acid</description>
    <arm_group_label>Valproic acid</arm_group_label>
    <other_name>Depakine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven or suspected diffuse astrocytoma (Isocytrate Dehydrogenase-1
             (IDH-1) wildtype or IDH-1 mutated), diffuse oligodendroglioma (IDH-1 mutated and
             1p/19q co-deleted), anaplastic astrocytoma (IDH-1 wildtype or IDH-1 mutated),
             anaplastic oligodendroglioma (IDH-1 mutated and 1p/19q co-deleted), glioblastoma
             (IDH-1 wild-type or IDH-1 mutated), or diffuse astrocytoma not otherwise specified
             (NOS), anaplastic astrocytoma NOS, oligodendroglioma NOS, oligoastrocytoma NOS,
             anaplastic oligoastrocytoma NOS, anaplastic oligodendroglioma NOS or glioblastoma
             NOS.

          -  Adult patients: â‰¥18 years of age

          -  First epileptic seizure, no longer than 2 weeks ago

          -  Monotherapy with antiepileptic drugs is considered most appropriate at the time of
             randomization

          -  Willing to provide written informed consent

        Exclusion Criteria:

          -  Previously treated with antiepileptic drugs, except emergency treatment in the past 2
             weeks

          -  History of non-brain tumor related epilepsy

          -  Pregnancy

          -  History of a status epilepticus

          -  Presence of contra-indications for use of levetiracetam or valproic acid
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 7, 2017</lastchanged_date>
  <firstreceived_date>February 7, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>j.a.f.koekkoek</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
